Saturday 17 October 2026
Export WINT’s income statement to Excel — free account
Windtree Therapeutics, Inc.
WINT Healthcare Biotechnology
In the quarter to September 2025, EPS grew 99.5% and free cash flow grew 1.12%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow WINT
| Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 5 | 4 | 2 | 4 |
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | 228.59 | 1,696,184.62 | 475,684.11 | 698,506.32 |
Altman Z-Score |
— | — | — | — | — | (7.03) | 35,474.06 | 12,534.28 | 21,759.50 |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | (17.51) | (17.20) | (685.41) | (239.28) |
P/Operating CF |
— | — | — | — | — | (21.02) | (489,868.86) | (146,919.91) | (205,377.96) |
P/B ratio |
— | — | — | — | — | 1.53 | 44,525.03 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | — | — | — | 222.99 | 1,696,183.41 | 475,703.16 | 698,515.84 |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | (4.54) | (192,178.94) | (33,567.08) | (42,465.37) |
EV/FCF |
— | — | — | — | — | (4.50) | (192,288.61) | (33,528.84) | (42,146.66) |
Quick Ratio |
0.31 | 1.08 | 2.51 | 4.54 | 2.76 | 2.89 | 1.22 | 0.15 | 0.42 |
Current Ratio |
0.45 | 1.35 | 3.00 | 4.77 | 2.96 | 3.05 | 1.24 | 0.19 | 0.54 |
Net Debt/EBITDA |
0.03 | (0.63) | (0.43) | 0.22 | (0.03) | 0.11 | 0.14 | (0.61) | (0.54) |
Debt/Assets |
3.44% | 47.01% | 40.19% | 20.45% | 15.75% | 16.62% | 19.24% | 448.16% | 257.76% |
Debt/Equity |
0.10 | 4.49 | 1.52 | 0.37 | 0.26 | 0.26 | 0.34 | (0.63) | (0.87) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.23 | 0.08 |
Operating CF/Net income |
2.81 | 0.66 | 0.50 | 0.35 | 0.78 | 0.90 | 0.45 | 0.85 | 0.85 |
Capex/Depreciation |
(0.07) | 0.00 | 0.01 | (0.01) | (1.73) | (0.53) | 0.01 | (0.02) | (0.13) |
Interest Coverage |
(111.23) | (411.94) | (779.87) | (677.89) | (242.54) | (50.29) | (11.49) | (12.10) | (15.11) |
| (81.98%) | (302.78%) | (151.11%) | (121.39%) | (45.08%) | (38.41%) | (157.29%) | 94.09% | 384.07% | |
| (18.20%) | (57.68%) | (69.55%) | (72.08%) | (28.09%) | (23.05%) | (56.63%) | (380.44%) | (146.05%) | |
ROIC |
(178.02%) | (89.99%) | (135.31%) | (138.69%) | (26.92%) | (21.57%) | (15.35%) | 0.00% | 0.00% |
Return on Tangible Assets |
180.97% | (1,295.72%) | (756.62%) | (345.45%) | (252.23%) | (163.13%) | (596.98%) | 287.29% | 767.84% |
Average Days of Receivables |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6,407.58% | 590.72% | 1,170.10% | 1,552.64% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6,264.65% | 415.04% | 448.28% | 410.04% |
Intangible Assets out of Total Assets |
0.87 | 0.78 | 0.75 | 0.64 | 0.82 | 0.78 | 0.78 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,394.44% | 53.41% | 111.45% | 82.52% |
Graham Net Nets |
— | — | — | — | — | (0.18) | 0.00 | 0.00 | 0.00 |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 53,264.97 | 56,917.09 |
Earnings Yield |
— | — | — | — | — | (19.52%) | (64.76%) | (788.64%) | (60.59%) |
Free Cash Flow Yield |
— | — | — | — | — | (21.66%) | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 990.00 | 0.40 | 1.44 | 4.91 |
Operating CF per Share |
(292.81) | (3,124.88) | (27,788.57) | (39,440.00) | (84,383.33) | (123,315.00) | (3.51) | (20.47) | (80.74) |
Capex per Share |
(0.23) | (3.49) | 281.43 | (465.00) | (970.00) | (955.00) | 0.00 | (0.02) | (0.61) |
Free Cash Flow per Share |
(293.04) | (3,128.37) | (27,507.14) | (39,905.00) | (85,353.33) | (124,270.00) | (3.51) | (20.50) | (81.35) |
Cash per Share |
33.82 | 1,004.42 | 8,817.14 | 37,246.67 | 56,433.33 | 112,890.00 | 5.60 | 1.77 | 13.43 |
Shareholders Equity per Share |
190.04 | 788.60 | 14,302.86 | 69,801.67 | 231,840.00 | 374,675.00 | 15.16 | (23.27) | (69.30) |
Interest Debt per Share |
0.00 | 0.00 | 0.02 | 0.03 | 0.06 | 0.10 | 0.00 | 0.00 | 0.00 |
Book value per Share |
190.04 | 788.60 | 14,302.86 | 69,801.67 | 231,840.00 | 374,675.00 | 15.16 | (23.27) | (69.30) |
Free Cash Flow |
(15.41) | (13.45) | (19.25) | (23.94) | (25.61) | (24.85) | (15.77) | (21.07) | (33.84) |
Working Capital |
(3.14) | 1.38 | 4.92 | 18.57 | 11.99 | 16.04 | 5.02 | (9.52) | (6.20) |
Capital Expenditures |
(0.01) | (0.01) | 0.20 | (0.28) | (0.29) | (0.19) | 0.01 | (0.02) | (0.25) |
Net Current Asset Value |
(15.30) | (23.64) | (20.56) | (9.42) | (25.21) | (20.18) | (25.63) | (25.03) | (31.33) |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.96 | 0.00 | 0.02 | 0.12 |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
1.63 | 17.16 | 76.25 | 44.72 | 0.18 | 0.45 | 1.28 | 1.25 | 1.86 |
Cash ROIC |
(121.04%) | (58.63%) | (61.25%) | (30.11%) | (24.56%) | (21.19%) | (13.57%) | 296.54% | (1,925.09%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Payables |
1.34 | 0.53 | 0.47 | 0.93 | 1.43 | 2.56 | 2.87 | 2.07 | 1.09 |
Average Assets |
30.14 | 35.18 | 56.37 | 93.84 | 115.93 | 119.19 | 61.37 | 6.52 | 27.04 |
Average Common Equity |
6.69 | 6.70 | 25.95 | 55.72 | 72.24 | 71.52 | 22.10 | (26.37) | (10.28) |
Columns are period end dates